Cue Biopharma Reports Q4 & FY25 Financial Results: Collaboration Revenue Up, Net Income Surges

Cue Biopharma reported Q4 and FY25 financial results, with collaboration revenue increasing to $21.94 million from $1.58 million in the prior year. Net income for Q4 was $1.59 million, or $0.01 per share, compared to a net loss of $9.50 million, or $0.13 per share, in the prior year. The company had $27.1 million in cash and cash equivalents as of December 31, 2025.